• 1
    Mayes MD. Scleroderma epidemiology [review]. Rheum Dis Clin North Am 2003; 29: 23954.
  • 2
    Altman RD, Medsger TA Jr, Bloch DA, Michel BA. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991; 34: 40313.
  • 3
    Diot E, Giraudeau B, Diot P, Degenne D, Ritz L, Guilmot JL, et al. Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis? Chest 1999; 116: 71520.
  • 4
    Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48: 51622.
  • 5
    White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132: 94754.
  • 6
    Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, et al, and the Scleroderma Lung Study Group. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 2005; 52: 592600.
  • 7
    Gildea TR, Arroliga AC, Minai OA. Treatments and strategies to optimize the comprehensive management of patients with pulmonary arterial hypertension. Cleve Clin J Med 2003; 70 Suppl 1: S1827.
  • 8
    Denton CP, Black CM. Pulmonary hypertension in systemic sclerosis [review]. Rheum Dis Clin North Am 2003; 29: 33549, vii.
  • 9
    Laing TJ, Gillespie BW, Toth MB, Mayes MD, Gallavan RH Jr, Burns CJ, et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum 1997; 40: 73442.
  • 10
    Morgan C, Knight C, Lunt M, Black CM, Silman AJ. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis 2003; 62: 14650.
  • 11
    Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 243744.
  • 12
    Briggs DC, Vaughan RW, Welsh KI, Myers A, duBois RM, Black CM. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet 1991; 338: 6612.
  • 13
    Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 2003; 5: 8093.
  • 14
    Greidinger EL, Flaherty KT, White B, Rosen A, Wigley FM, Wise RA. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest 1998; 114: 8017.
  • 15
    Nishioka K, Katayama I, Kondo H, Shinkai H, Ueki H, Tamaki K, et al, and the Scleroderma Research Committee Japan. Epidemiological analysis of prognosis of 496 Japanese patients with progressive systemic sclerosis (SSc). J Dermatol 1996; 23: 67782.
  • 16
    Hutchinson J, Smith AD. Ethnicity. Oxford: Oxford University Press; 1996.
  • 17
    Reveille JD, Fischbach M, McNearney T, Friedman AW, Aguilar MB, Lisse J, et al. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001; 30: 33246.
  • 18
    The Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 58190.
  • 19
    Rodnan GP, Lipinski E, Luksick J. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 1979; 22: 13040.
  • 20
    Silman A, Harrison M, Brennan P, and the ad hoc International Group on the Assessment of Disease Outcome in Scleroderma. Is it possible to reduce observer variability in skin score assessment of scleroderma? J Rheumatol 1995; 22: 127780.
  • 21
    Pope JE, Bellamy N. Outcome measurement in scleroderma clinical trials [review]. Semin Arthritis Rheum 1993; 23: 2233.
  • 22
    Watters LC, King TE, Schwarz MI, Waldron JA, Stanford RE, Cherniack RM. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1986; 133: 97103.
  • 23
    Cohen S, Mermelstein R, Kamarch T, Hoberman HM. Measuring the functional components of social support. In: SarasonIB, SarasonBR, editors. Social support: theory, research, applications. Boston: Martinus Nijhoff; 1985.
  • 24
    Pilowsky L, Spence ND. Illness behavior questionnaire (IBQ). In: CorcoranK, FischerJ, editors. Measures for clinical practice: a source book. New York: The Free Press; 1996. p. 182.
  • 25
    Engle EW, Callahan LF, Pincus T, Hochberg MC. Learned helplessness in systemic lupus erythematosus: analysis using the Rheumatology Attitudes Index. Arthritis Rheum 1990; 33: 2816.
  • 26
    Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 47383.
  • 27
    Stewart AL, Hays RD, Ware JE Jr. The MOS short-form general health survey: reliability and validity in a patient population. Med Care 1988; 26: 72435.
  • 28
    Feghali-Bostwick C, Medsger TA Jr, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003; 48: 195663.
  • 29
    Reveille JD, Durban E, MacLeod-St Clair MJ, Goldstein R, Moreda R, Altman RD, et al. Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis). J Clin Invest 1992; 90: 97380.
  • 30
    Tan FK, Wang N, Kuwana M, Chakraborty R, Bona CA, Milewicz DM, et al. Association of fibrillin 1 single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. Arthritis Rheum 2001; 44: 893901.
  • 31
    Steen VD, Lanz JK Jr, Conte C, Owens GR, Medsger TA Jr. Therapy for severe interstitial lung disease in systemic sclerosis: a retrospective study. Arthritis Rheum 1994; 37: 12906.
  • 32
    Vlachoyiannopoulos PG, Dafni UG, Pakas I, Spyropoulou-Vlachou M, Stavropoulos-Giokas C, Moutsopoulos HM. Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele. Ann Rheum Dis 2000; 59: 35967.
  • 33
    Chang B, Wigley FM, White B, Wise RA. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 2003; 30: 2398405.
  • 34
    Sacks DG, Okano Y, Steen VD, Curtiss E, Shapiro LS, Medsger TA Jr. Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: association with serum anti-U3RNP antibody. J Rheumatol 1996; 23: 63942.
  • 35
    Tormey VJ, Bunn CC, Denton CP, Black CM. Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology (Oxford) 2001; 40: 115762.
  • 36
    Schachter LM, Dixon J, Pierce RJ, O'Brien P. Severe gastroesophageal reflux is associated with reduced carbon monoxide diffusing capacity. Chest 2003; 123: 19328.
  • 37
    Kinuya K, Nakajima K, Kinuya S, Michigishi T, Tonami N, Takehara K. Esophageal hypomotility in systemic sclerosis: close relationship with pulmonary involvement. Ann Nucl Med 2001; 15: 97101.
  • 38
    Scussel-Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002; 81: 15467.
  • 39
    Patel KV, Eschbach K, Ray LA, Markides KS. Evaluation of mortality data for older Mexican Americans: implications for the Hispanic paradox. Am J Epidemiol 2004; 159: 70715.
  • 40
    Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP, Hazuda HP. All-cause and cardiovascular mortality among Mexican-American and non-Hispanic White older participants in the San Antonio Heart Study: evidence against the “Hispanic paradox”. Am J Epidemiol 2003; 158: 104857.
  • 41
    Franzini L, Ribble JC, Keddie AM. Understanding the Hispanic paradox. Ethn Dis 2001; 11: 496518.
  • 42
    Morelli S, Barbieri C, Sgreccia A, Ferrante L, Pittoni V, Conti F, et al. Relationship between cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol 1997; 24: 815.
  • 43
    Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1012 Italian patients. Medicine (Baltimore) 2002; 81: 13953.
  • 44
    Atamas SP, White B. Cytokine regulation of pulmonary fibrosis in scleroderma [review]. Cytokine Growth Factor Rev 2003; 14: 53750.